偏头痛生物标志物的研究进展

Research progress in biomarkers of migraine

偏头痛是临床常见神经系统疾病,也是世界第7位致残性疾病,但疾病的复杂性为其诊断和治疗带来了极大的阻碍。随着生物标志物研究的不断进展,我们对偏头痛的病理生理学有了更深入的理解,也为偏头痛患者的诊断和治疗带来了更多的可能,多种生物标志物成为偏头痛治疗的潜在靶点,如降钙素基因相关肽、5-羟色胺1F(5-HT1F)、谷氨酸、垂体腺苷酸环化酶、食欲素等等,部分靶向药物的疗效也已得到临床证实。尽管偏头痛生物标志物的研究已经取得重大突破,但也只是处于初始阶段,从他们的检测到实际临床应用仍然是一个挑战,未来仍需探索特异性和敏感性俱佳的临床标志物,并以此来促进个性化、精准化医疗的发展。

Migraine is a common clinical neurological disease and the seventh disabling disease in the world, however,the complexity of the disease has greatly hindered its diagnosis and treatment. With the continuous development of migraine biomarkers studies, we get a further understanding of its pathophysiological mechanisms. These findings have brought more possibilities for the diagnosis and treatment of migraineurs.A variety of biomarkers have become potential targets for migraine therapy, such as calcitonin gene-related peptides, serotonin 1 F(5-HT1 F), glutamate, pituitary adenylate cyclase-activating peptide, orexin, etc,the efficacy of some targeted drugs has been proved.Although great breakthroughs have been witnessed, we are only at the initial stage. The process from their detection to actual clinical application is still a challenge. In the future, it is still critical to explore clinical markers with better specificity and sensitivity so as to promote the development of personalized and precise medical treatment for migraineurs.